In this video, analysts David Williamson and Max Macaluso discuss United Therapeutics and Discovery Laboratories' 15% intraday plunges. One received an FDA rejection, and the other had a familiar problem rear its ugly head. Watch and find out what this means for these stocks, their competitors, and investors.



David Williamson, Max Macaluso, and The Motley Fool have no positions in the stocks mentioned above. Motley Fool newsletter services recommend Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.